

“Reverse Translational Studies to Understand the Molecular Mechanisms of Chemotherapy-Induced Peripheral Neuropathy”

11 a.m.-12 p.m. Friday, April 26
3rd Floor, Health 2 Building, University of Houston Campus



Deanna L. Kroetz, Ph.D.
Dean and Professor of Pharmaceutics & Pharmacology,
The Ohio State University College of Pharmacy

Deanna Kroetz is Dean and Professor of The Ohio State University College of Pharmacy. Prior to joining Ohio State in late 2023, Dr. Kroetz was Professor and Chair of Bioengineering and Therapeutic Sciences and the Jere E. Goyan Presidential Chair for the Advancement of Pharmacy in the University of California San Francisco School of Pharmacy (UCSF). She received her B.S. degree in Pharmacy from The Ohio State University and her Ph.D. in Pharmaceutics from the University of Washington, under the mentorship of Dr. René Levy. Dr. Kroetz was a PRAT Fellow in the Laboratory of Molecular Carcinogenesis at the National Cancer Institute under the mentorship of Dr. Frank Gonzalez before joining the faculty at UCSF.

She has received numerous awards, including the American Association of Pharmaceutical Scientists New Investigator Award in Pharmacokinetics, Pharmacodynamics and Drug Metabolism, the Josephine Failer Award from the Ohio State University Alumni Association, the Leon Goldberg Young Investigator Award and the Rawls Palmer Progress in Medicine Award from the American Society for Clinical Pharmacology and Therapeutics, fellow designation of the AAPS and the American Association for the Advancement of Science, and the Distinguished Alumna Award for Excellence in Pharmaceutical Sciences and Research from the University of Washington School of Pharmacy.

Her research interests are focused on understanding the mechanisms underlying interindividual variation in drug response and toxicity. The current research focus of her lab is on chemotherapy-induced peripheral neuropathy (CIPN). The Kroetz lab uses genomic approaches such as genome-wide genotyping and exome sequencing to identify genetic biomarkers of chemotherapy toxicity. The Kroetz lab is also studying the role of the multidrug resistance protein MRP4 in immunosensitivity and response to immunotherapies. Dr. Kroetz served as the Director of the Pharmaceutical Sciences and Pharmacogenomics Graduate Program at UCSF from 2010 to 2019. She is currently the Deputy Editor-in-Chief of Clinical and Translational Science.

Persons with disabilities who desire accommodations should contact
Egina Villalobos-Hernandez at evillal@central.uh.edu or 713-743-7010 by April 19.
The University of Houston is an EO/AA institution.